The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients
This trial is active, not recruiting.
|Conditions||disorders associated with peritoneal dialysis, hyperuricemia|
|Sponsor||Shanghai 10th People's Hospital|
|Start date||January 2015|
|End date||January 2017|
|Trial size||50 participants|
|Trial identifier||NCT02338128, FPD2015|
The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.
cardiovascular events (heart failure, myocardial infarction, unstable angina which need hospitalization，heart surgery, or death caused by cardiovascular disease.)
time frame: 1 year
Serum uric acid
time frame: 1st month, 2nd month, 3rd month, 6th month, 9th month, 12th month
cardiovascular function (Heart construction and cardiac ejection fraction determined by echocardiography; blood test: cardiac markers including troponin,myoglobin and creatinine kinase, MB isoenzyme (CK-MB), brain natriuretic peptide)
time frame: 6 months
Male or female participants from 18 years up to 75 years old.
- Peritoneal dialysis for more than 3 months with hyperuricemia.
- Acute hepatopathy or liver dysfunction (Aspartate transaminase and/or alanine aminotransferase exceed 2 times of normal range)
- Heart failure (stage IV, NYHA), unstable angina, acute stroke
- Severe lung disease or cancer
- unable to sign the informed consent form or disagree following-up.
|Official title||The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study|
|Description||Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia. Use Febuxostat to control their serum uric acid for 1 year. To observe the cardiovascular events of patients, and compare and evaluate the changes of heart function, heart construction, serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat treatment.|
Call for more information